Actively Recruiting
A Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986523 Alone and in Combination With Anti-Cancer Agents in Participants With Advanced Solid Malignancies
Led by Bristol-Myers Squibb · Updated on 2026-04-13
252
Participants Needed
8
Research Sites
150 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The purpose of this study is to evaluate the safety, tolerability, and efficacy of BMS-986523 alone and in combination with anti-cancer agents in participants with advanced solid malignancies
CONDITIONS
Official Title
A Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986523 Alone and in Combination With Anti-Cancer Agents in Participants With Advanced Solid Malignancies
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Participants must have a confirmed diagnosis of a locally advanced, unresectable, or metastatic solid tumor with a KRAS mutation or amplification.
- For Arm D, participants must have PD-L1 expression of 50% or higher.
- Participants must have previously received, be ineligible for, or decline standard-of-care cancer treatments after being informed.
You will not qualify if you...
- Participants with untreated central nervous system metastases are excluded.
- Participants with another cancer requiring treatment or a prior cancer active within 2 years before treatment are excluded.
- Participants with a history or evidence of interstitial lung disease or active, non-infectious pneumonitis are excluded; radiation pneumonitis in the radiation field is allowed.
- Participants with a history of severe skin reactions like Stevens-Johnson Syndrome or toxic epidermal necrolysis are excluded.
- Additional protocol-defined inclusion/exclusion criteria apply.
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 8 locations
1
Local Institution - 0009
Baltimore, Maryland, United States, 21287
Not Yet Recruiting
2
NEXT Oncology
San Antonio, Texas, United States, 78229
Actively Recruiting
3
START Mountain Region
West Valley City, Utah, United States, 84119
Actively Recruiting
4
NEXT Virginia
Fairfax, Virginia, United States, 22031
Actively Recruiting
5
Local Institution - 0002
Vancouver, British Columbia, Canada, V5Z 4E6
Not Yet Recruiting
6
Princess Margaret Cancer Centre
Toronto, Ontario, Canada, M5G 2M9
Actively Recruiting
7
Local Institution - 0006
Badalona, Barcelona [Barcelona], Spain, 08916
Not Yet Recruiting
8
Local Institution - 0008
Hortaleza, Madrid, Spain, 28050
Not Yet Recruiting
Research Team
B
BMS Clinical Trials Contact Center www.BMSClinicalTrials.com
CONTACT
F
First line of the email MUST contain NCT # and Site #.
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
6
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here